Core Viewpoint - The company, Kangnibei, anticipates that its export business will account for approximately 8% of total revenue in 2024, focusing on regions such as India, the Middle East, Pakistan, and Europe [2] Group 1 - The export products primarily include active pharmaceutical ingredients such as Azithromycin, Amikacin Sulfate, Dexamethasone Hydrochloride, and Clarithromycin [2]